Population-level virulence factors amongst pathogenic bacteria: Relation to infection outcome

Future Microbiology

Volumn 3, Issue 1, 2008, Pages 31-42

  Hu, Fen Ze ^a,b   Ehrlich, Garth D ^a,b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bacteria; Biofilms; Distributed genome hypothesis; Horizontal gene transfer; Pathogenesis; Population level virulence factors; Quorum sensing; Supragenome

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; MACROLIDE; NANOWIRE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STAPHYLOCOCCUS TOXIN; TETRACYCLINE DERIVATIVE; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; BACTERIOPLANKTON; BIOFILM; CELL COMMUNICATION; DRUG TOLERANCE; HORIZONTAL GENE TRANSFER; HOST RESISTANCE; HUMAN; LIFE CYCLE; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; STAPHYLOCOCCUS AUREUS; TOXIC SHOCK SYNDROME; ANIMAL; BACTERIUM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; VIRULENCE;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; VIRULENCE; VIRULENCE FACTORS;

EID: 39049092784     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.1.31     Document Type: Review

References (91)

1. Ehrlich GD, Hu FZ, Shen K, Stoodley P, Post JC: Bacterial plurality as a general mechanism driving persistence in chronic infections. Clin. Orthop. Relat. Res. 437, 20-24 (2005).
2. Ehrlich GD, Veeh R, Wang X et al.: Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 287, 1710-1715 (2002).
3. Costerton JW, Veeh R, Shirtliff M, Pasmore M, Post JC, Ehrlich GD: The application of biofilm science to the study and control of chronic bacterial infections. J. Clin. Invest. 117 (1), 278 (2003).
4. Fuqua WC, Winans SC, Greenberg EP: Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J. Bacteriol. 176(2), 269-275 (1994).
5. Bassier BL, Losick R: Bacterially speaking. Cell 125(2), 237-246 (2006).
6. Waters CM, Bassler BL: Quorum sensing: cell-to-cell communication in bacteria. Annu. Rev. Cell. Dev. Biol. 21, 319-346 (2005).
7. Yarwood JM, Schlievert PM: Quorum sensing in Staphylococcus infections. J. Clin. Invest. 112(11), 1620-1625 (2003).
8. Costerton JW, Montanaro, L, Arciola CR: Biofilm in implant infections: its pruduction and regulation. Int. J. Artif. Organs 28(11), 1062-1068 (2005).
9. Shen K, Antalis P, Gladitz J et al.: Identification, distribution, and expression of novel genes in ten clinical isolates of nontypeable Haemophilus influenzae. Infect. Immun. 73, 3479-3491 (2005).
10. Shen K, Antalis P, Gladitz J et al.: Characterization, distribution and expression of novel genes among eight clinical isolates of Streptococcus pneumoiae. Infect. Ammun. 74(1), 321-330 (2006).
11. Shen K, Sayeed S, Antalis P et al.: Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel (nonPAO1) genes among clinical isolates. Infect. Immun. 74(9), 5272-5283 (2006).
12. Hogg JS, Hu FZ, Janto, B et al.: Characterization and modeling of the Haemophilus influenzae core and supragenome based on the complete genomic sequences of rd and 12 clinical nontypeable strains. Genome Biol. 8(6), R103 (2007).
13. Hiller NL, Janto B, Hogg JS et al.: Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: insights into the pneumococcal supragenome. J. Bacteriol. (2007) (In Press).
14. Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doem GV: Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J. Infect. Dis. 180(2), 404-409 (1999).
15. Mukundan D, Ecevit Z, Patel M, Marrs CF, Gilsdorf JR: Pharyngeal colonization dynamics of Haemophilus influenzae and Haemaphilus haemalyticus in healthy adult carriers. J. Clin. Microbid. 45(10), 3207-3217 (2007).
16. Hu FZ: Biofilms as bacterial breeding grounds: a counterpoint to the adaptive host response. Presented at: 9th International Symposium an Recent Advances in Otitis Media. St Pete Beach, FL, USA, 7 June 2007.
17. Costerton JW, Geesey GG, Cheng K-J: "How bacteria stick". Sci. Am. 238, 86-95 (1978).
18. Marrie TJ, Costerton JW: Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J. Clin. Microbiol. 22(6), 924-933 (1985).
19. Costerton JW: Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin. Orthop. Relat. Res. 437, 7-11 (2005).
20. Sung JY, Leung JW, Olson ME, Lundberg MS, Costerton JW: Demonstration of transient bacterobilia by foreign body implantation in feline biliary tract. Dig. Dis. Sci. 36(7), 943-948 (1991).
21. Stewart L, Griffiss JM, Jarvis GA, Way LW: Gallstones containing bacteria are biofilms: bacterial slime production and ability to form pigment solids determines infection severity and bacteremia. J. Gastrointest. Surg. 11(8), 977-983; discussion 983-984 (2007).
22. Nickel JC, Costerton JW, McLean RJ, Olson M: Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J. Antimicrob. Chemother. 33(Suppl. A), S31-S41 (1994).
23. Rayner MG, Zhang Y, Gorry MC, Chen Y, Post JC, Ehrlich GD: Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA 279, 296-299 (1998).
24. Post JC, Stoodley P, Hall-Stoodley L, Ehrlich GD: The role of biofilms in otolaryngologic infections. Curr. Opin. Otolaryngol. Head Neck Surg. 12 (3), 185-190 (2004).
25. Hall-Stoodley L, Hu FZ, Stoodley P et al.: Direct evidence that otitis media with effuslon is a biofilm disease. JAMA 296, 202-211 (2006).
26. Palmer J: Bacterial biofilms in chronic rhinosinusitis: Ann. Otol. Rhinol. Laryngol. 196(Suppl.), 35-39 (2006).
27. Sanderson AR, Leid JG, Hunsaker D: Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 116 (7), 1121-1126 (2006).
28. Chole RA, Faddis BT: Evidence for microbial biofilms in cholesteatomas. Arch. Otolaryngol. Head Neck Surg. 128(10), 1129-1133 (2002).
29. Chole RA, Faddis BT: Anatomical evidence of microbial biofilms in tonsillar tissues: a possible mechanism to explain chronicity. Arch. Otolaryngol. Head Neck Surg. 129(6), 634-636 (2003).
30. Zuliani G, Carron M, Gurrola J et al.: Identification of adenoid biofilms in chronic rhinosinusitis. Int. J. Pediatr. Otorhinolaryngol. 70(9), 1613-1617 (2006).
31. Davis SC, Martinez L, Kirsner R: The diabetic foot: the importance of biofilms and wound bed preparation. Curr. Diab. Rep. 6(6), 439-445 (2006).
32. Marquis RE: Oxygen metabolism, oxidative stress and acid-base physiology of dental plaque bioflims. J. Ind. Microbiol. 15(3), 198-207 (1995).
33. Darveau RP, Tanner A, Page RC: The microbial challenge in periodontitis. Periodontol. 2000 14, 12-32 (1997).
34. Paster BJ, Olsen I, Aas JA, Dewhirst FE: The breadth of bacterial diversity in the human periodontal pocket and other oral sites. Periodontol. 2000 42, 80-87 (2006).
35. Raghavendran K, Mylotte JM, Scannapieco FA: Nursing home-associated pneumonia, hospital-acquired pneumonia and ventilator-associated pneumonia: the contribution of dental biofilms and periodontal inflammation. Periodontol. 2000 44, 164-177 (2007).
36. Chen C: Periodontitis as a biofilm infection. J. Calif. Dent. Assoc. 29(5), 362-369 (2001).
37. Davey ME, Duncan MJ: Enhanced biofilm formation and loss of capsule synthesis: deletion of a putative glycosyltransferase in Porphyromonas gingivalis. J. Bacteriol. 188(15), 5510-5523 (2006).
38. Al-Ahmad A, Wunder A, Auschill TM et al.: The in vivo dynamics of Streptococcus spp., Actinomyces naeslundii, Fusobacterium nucleatum and Veillonella spp. in dental plaque biofilm as analysed by five-colour multiplex fluorescence in situ hybridization. J. Med. Microbiol. 56(Pt 5), 681-687 (2007).
39. Ehrlich GD, Hu ZF, Post JC: Role for biofilms in infectious disease. In: Microbial Biofilms. Ghannoum M, O'Toole GA (Eds). ASM Press, Washington, DC, USA 332-358 (2004).
40. Hall-Stoodley L, Costerton JW, Stoodley P: Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2(2), 95-108 (2004).
41. Hall-Stoodley L, Stoodley P: Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 13(1), 7-10 (2005).
42. Purevdoij B, Costerton JW, Stoodley P: Influence of hydrodynamics and cell signaling on the structure and behavior of Pseudamonas aeruginosa biofilms. Appl. Environ. Microbiol, 68(9), 4457-4464 (2002).
43. Kiapper I, Rupp CJ, Cargo R, Purvedorj B, Stoodley P: Viscoelastic fluid description of bacterial biofilm material properties. Biotechnol. Bioeng. 80(3), 289-296 (2002).
44. Dunsmore BC, Jacobsen A, Hall-Stoodley L, Bass CJ, Lappin-Scott HM, Stoodley P: The influence of fluid shear on the structure and material properties of sulphate-reducing bacterial biofilms. J. Ind. Microbiol. Biotechnol. 29(6), 347-353 (2002).
45. Stoodley P, Cargo R, Rupp CJ, Wilson S, Klapper I: Biofilm material properties as related to shear-induced deformation and detachment phenomena. J. Ind. Microbiol. Biotechnol. 29(6), 361-367 (2002).
46. Towler BW, Rupp CJ, Cunningham AB, Stoodley P: Viscoelastic properties of a mixed culture biofilm from rheometer creep analysis. Biofouling 19(5), 279-285 (2003).
47. Shaw T, Winston M, Rupp CJ, Klapper I, Stoodley P: Commonality of elastic relaxation times in biofilms. Phys. Rev. Lett. 93(9), 098102 (2004).
48. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS: Extracellular DNA required for bacterial biofilm formation. Science 295(5559), 1487 (2002).
49. Jurcisek JA, Bakaletz LO: Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J. Bacteriol. 189(10), 3868-3875 (2007).
50. Aitken ML: Clinical trials of recombinant human DNase in cystic fibrosis patients. Monaldi Arch. Chest Dis. 48(6), 653-656 (1993).
51. Bryson HM, Sorkin EM: Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 48(6), 894-906 (1994).
52. Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS: Oxygen limitation contributes to antibiotic tolerance of Pseudomanas aeruginosa in biofilms. Antimicrob. Agents Chemother. 48, 2659-2664 (2004).
53. Borriello G, Richards L, Ehrlich GD, Stewart PS: Arginine or nitrate enhance antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother. 50(1), 382-384 (2006).
54. Lederberg J, Zinder N: Concentration of biochemical mutants of bacteria with penicillin. J. Am. Chem. Soc. 70, 4267-4268 (1948).
55. Davis BD: Isolation of biochemically deficient mutants of bacteria by penicillin. J. Am. Chem. Soc. 70, 4267 (1948).
56. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA: A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426(6964), 306-310 (2003).
57. Gilbert P, Maira-Litran T, McBain AJ, Rickard AH, Whyte FW: The physiology and collective recalcitrance of microbial biofilm communities. Adv Microb Physiol. 46, 202-256 (2002).
58. Leid JG, Shirtliff ME, Costerton JW, Stoodley AP: Human leukocytes adhere to, penetrate, and respond to Staphylococcus aureus biofilms. Infect. Immun. 70(11), 6339-6345 (2002).
59. Leid JG, Willson CJ, Shirtliff ME, Hassett DJ, Parsek MR, Jeffers AK: The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-γ-mediated macrophage killing. J. Immunol. 175(11), 7512-7518 (2005).
60. Cerca N, Jefferson KK, Oliveira R, Pier GB, Azeredo J: Comparative antibody-mediated phagocytosis of Staphyloccus epidermidis cells grown in a biofilm or in the planktonic state. Infect. Immun. 74(8), 4849-4855 (2006).
61. Camilli A, Bassler BL: Bacterial small-molecule signaling pathways. Science 311(5764), 1113-1116 (2006).
62. Gonzalez JE, Keshavan ND: Messing with bacterial quorum sensing. Microbiol. Mol. Biol. Rev. 70(4), 859-875 (2006).
63. Fuqua C, Parsek MR, Greenberg EP: Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu. Rev. Genet. 35, 439-468 (2001).
64. Fuqua C, Greenberg EP: Listening in on bacteria: acyl-homoserine lactone signalling. Nat. Rev. Mol. Cell Biol. 3(9), 685-695 (2002).
65. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilm: a common cause of persistent infections. Science 284 (5418), 1318-1322 (1999).
66. Parsek MR, Greenberg EP: Quorum sensing signals in development of Psedomonas aeruginosa biofilms. Methods Enzymol. 310, 43-55 (1999).
67. Parsek MR, Greenberg EP: Acyl-homoserine lactone quorum sensing in Gram-negative bacteria: a signaling mechanism involved in associations with higher organisms. Proc. Natl Acad. Sci. USA 97(16), 8789-8793 (2000).
68. Waters CM, Bassler BL: Quorum sensing: cell-to-cell communication in bacteria. Annu. Rev. Cell Dev. Biol. 21, 319-346 (2005).
69. Waters CM, Bassier BL: The Vibrio harveyi quorum-sensing system uses shared regulatory components to discriminate between multiple autoinducers. Genes Dev. 20(19), 2754-2767 (2006).
70. DeClerk N, Bouillaut L, Chaix D et al.: Structure of P1cR: insights into virulence regulation and evolution of quorum sensing in Gram-positive bacteria. Proc. Natl Acad. Sci. USA 104(47), 18490-18495 (2007).
71. Balaban N, Cirioni O, Giacometti A et al.: Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob. Agents Chemother. 51(16), 2226-2229 (2007).
72. Jensen PO, Bjarnsholt T, Phipps R et al.: Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153(Pt 5), 1329-1338 (2007).
73. Gram L, de Nys R, Maximilien R, Givskov M, Steinberg P, Kjelleberg S: Inhibitory effects of secondary metabolites from the red alga delisea pulchra on swarming motility of proteus mirabilis. Appl. Environ. Microbiol. 62(11), 4284-4287 (1996).
74. Manefield M, de Nys R, Kumar N et al.: Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology 145(Pt 2), 283-291 (1999).
75. Hentzer M, Wu H, Andersen JB et al.: Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22(15), 3803-3815 (2003).
76. Ehrlich GD: The biofilm and distributed genome paradigms provide a new theoretical structure for understanding chronic bacterial infections. Presented at: Inter Science Conference on Antimicrobials Agents and Chemotherapy. Chicago, IL, USA, 18 December, 2001.
77. Shen K, Wang X, Post JC, Ehrlich GD: Molecular and translational research approaches for the study of bacterial pathogenesis in otitis media. In: Evidence-based Otitis Media (2nd Edition). Rosenfeld R, Bluestone CD (Eds). BC Decker Inc., Hamilton, ON, USA 91-119 (2003).
78. Redfield RJ, Findlay WA, Bosse J, Kroll JS, Cameron AD, Nash JH: Evolution of competence and DNA uptake specificity in the Pasteurellaceae. BMC Evol. Biol. 6, 82 (2006).
79. Ecevit IZ, McCrea KW, Pettigrew MM et al.: Prevalence of the hifBC, hmw1A, hmw2A, hmwC, and hia genes in Haemophilus influenzae isolates. J. Clin. Microbiol. 42(7), 3065-3072 (2004).
80. Jefferies JM, Smith A, Clarke SC, Dowson C, Mitchell TJ: Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. J. Clin. Microbiol. 42(12), 5681-5688 (2004).
81. Jelsbak L, Johansen HK, Frost AL et al.: Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. Immun. 75(5), 2214-2224 (2007).
82. Kreth J, Merritt J, Zhu L, Shi W, Qi F: Cell density- and CornE-dependent expression of a group of mutacin and mutacin-like genes in Streptococcus mutans. FEMS Microbiol. Lett. 265(1), 11-17 (2006).
83. Prudhomme M, Attaiech L, Sanchez G, Martin B, Claverys JP: Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science 313(5783), 89-92 (2006).
84. Claverys JP, Havarstein LS: Cannibalism and fratricide: mechanisms and raisons d'etre. Nat. Rev. Microbiol. 5(3), 219-229 (2007).
85. Juhas M, Crook DW, Dimopoulou ID et al.: Novel type IV secretion system involved in propagation of genomic islands. J. Bacteriol. 189(3), 761-771 (2007).
86. Ramirez M, Tomasz A: Acquisition of new capsular genes among clinical isolates of antibiotic-resistant Streptococcus pneumoniae. Microb. Drug Resist. 5(4), 241-246 (1999).
87. Griffith F: The significance of pneumococcal types. J. Hyg. 27, 113-159 (1928).
88. Avery OT, MacLeod CM, McCarty M: Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J. Exp. Med. 89, 137-158 (1944).
89. Schaudinn C, Stoodley P, Kainovic A et al.: Bacterial biofilms, other structures seen as mainstream concepts get used to it: bacterial microcolonies form regular shapes, such as nanowires or honeycomb-like structures. Microbe 2(5), 231-237 (2007).
90. Gorby YA, Yanina S, McLean JS et al.: Electrically conductive bacterial nanowires produced by Shewanella oneidensis strain MR-1 and other microorganisms. Proc. Natl Acad. Sci. USA 103(30), 11358-11363 (2006).
91. Bretschger O, Obraztsova A, Sturm CA et al.: An exploration of current production and metal oxide reduction by Shewanella oneidensis MR-1 wild type and mutants. Appl. Environ. Microbiol. 73(21), 7003-7012 (2007).